Fintepla® | UCB
UCB's Global Corporate Website

Fintepla®

 

 

In the European Union and in the UK, Fintepla® is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Prescribing information Europe Sourced from https://www.ema.europa.eu

 

“This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions"

 
In the US, FINTEPLA® is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.


Prescribing information USA

As of March 7, 2022, Zogenix Inc. and all its affiliates worldwide are part of the UCB Group of Companies.